important

Thymoma is one of the most common primary tumors in the anterior mediastinum, representing a group of diseases originating from different thymic epithelial cells, characterized by unique clinical and pathological features, often accompanied by various paraneoplastic syndromes. During the "Multidisciplinary Oncology Committee" session held at the 2023 European Lung Cancer Congress (ELCC), several experts discussed the treatment strategies for Stage III thymoma based on a case study. Dr. Andreas Rimner from Memorial Sloan Kettering Cancer Center presented on "The Timing of Radiotherapy in the Treatment of Stage III Thymoma." In an interview with Oncology Frontier, Andreas Rimner shares insights into the role of radiotherapy in the treatment of Stage III thymoma.

The 2023 European Lung Cancer Congress (ELCC) recently concluded in Copenhagen. In an interview with Oncology Frontier, 2023 ELCC Scientific Co-Chairs Professor Martin Reck reviewed the most significant oral presentations of the conference and shared insights on the selection of first-line immunotherapy regimens.

On the first day of the 2023 European Lung Cancer Congress (ELCC), during the oral presentation session, Dr. P. Garrido Lopez from Ramón y Cajal University Hospital in Madrid, Spain, presented the long-term efficacy, safety, and predictive factors of amivantamab in the treatment of platinum-treated EGFR exon 20 insertion (EGFR ex20ins) mutant advanced non-small cell lung cancer (NSCLC) patients in the CHRYSALIS trial (Abstract No. 3O). In an interview with "Tumor Insight," P. Garrido Lopez further elucidated the results of the CHRYSALIS trial and its clinical significance.

At the recently concluded 2023 European Lung Cancer Congress (ELCC), Professor Luis Paz-Ares from Madrid University Hospital in Spain presented results from a Phase II trial called CARMEN-LC05 (NCT04524689). The results showed that the antibody-drug conjugate (ADC) targeting CEACAM5, Tusamitamab ravtansineA, in combination with or without pembrolizumab, and chemotherapy, produced responses in CEACAM5-positive non-squamous non-small cell lung cancer (NSCLC) patients in the first-line treatment, and it was well-tolerated.